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Abstract The aim of this study was to compare the efficacy and safety of salmeterol/fluticasone propionate
combination product (SFC) with fluticasone propionate (FP) plus oral montelukast (M) over 12 weeks in symptomatic
asthma patients.The study was a multinational, randomised, double-blind, double-dummy, parallel-group design in pa-
tients aged15 years. After a 4-week run-in during which all patients received FP100 mg twice daily, patientswere ran-
domised to inhaled SFC (50/100 mg) twice dailyor inhaled FP100 mg twice daily and oral M10mgonce daily.Patientskept
dailyrecords oftheir peakexpiratory flow (PEF), symptomscores anduse of rescuemedication.Over the12-weektreat-
ment period, the adjusted increase inmeanmorning PEF was significantly greater in the SFC group (36 l/min) than the
FP/Mgroup (19 l/min;Po0.001).Theimprovementin FEV1was also significantlygreaterinthe SFC group (meantreatment
difference 0.11l; Po0.001). SFC provided significantly better control of daytime and night-time symptoms and there
were fewer exacerbations. Patients in the SFC group were also significantly more likely to have a rescue-free day.
Bothtreatmentswere equally well tolerated.Combination therapy with FP plus salmeterol (SFC) produced significantly
greaterimprovementsinlung function andasthma controlthanthe additionofmontelukastto FP.r2002 Elsevier Science Ltd.
Allrights reserved.
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Worldwide, the rates of morbidity and mortality
associated with asthma are increasing (1,2). Improve-
ments to current asthma management are becoming in-
creasingly important as more information becomes
available on the e¡ects of untreated airway in£ammation
on disease progression (3). National and international
guidelines recommend that the goals of asthmamanage-
ment should be to control symptoms and prevent
exacerbations, thus leading to reductions in healthcare
burden and an improvement in the patient’s quality
of life (4,5). It is widely accepted that inhaled corticoster-
oids are the most e¡ective preventative treatmentReceived 8 April 2002, accepted in revised form 29 August 2002
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anti-in£ammatory medication available (6). For those
patients who remain symptomatic on inhaled corticos-
teroids, addition of a long-acting beta-agonist such
as salmeterol has been shown to produce greater
improvements in lung function and symptom
control than at least doubling the dose of inhaled corti-
costeroid (7^10). It is now well established that the com-
bination of long-acting beta-agonists and inhaled
corticosteroids is very e¡ective in treating both compo-
nents of asthma, in£ammation and smooth muscle
dysfunction (11).
The addition of a leukotriene receptor antagonist to
therapy has been proposed in current European data-
sheets as an alternative treatment strategy in those pa-
tients inadequately controlled on inhaled corticosteroids
(12), but their role has not been clari¢ed in treatment
guidelines (5,13). Leukotriene receptor antagonists have
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tivity (14). There is a modest increase in patients’ lung
function anddaytime asthma symptom scorewhenmon-
telukast is added to inhaled corticosteroid therapy (15).
This study compares the clinical e¡ect of the addition
of either salmeterol or montelukast to treatment with
an inhaled corticosteroid, £uticasone propionate (FP), in
adults with asthma who are symptomatic despite treat-
ment with inhaled corticosteroids. A recent study per-
formed in the U.S.A. has con¢rmed that salmeterol/
£uticasone propionate combination (SFC) is superior to
therapy with FP plus montelukast (16). The aim of the
current study was to con¢rm these ¢ndings in a geogra-
phical area with di¡erent clinical practices, to provide
guidance to clinicians for the selection of themost e¡ec-
tive and safest therapeutic approach for patientswho are
receiving inhaled corticosteroids and who require addi-
tional therapy. Duplication of clinical trial ¢ndings is a
good clinical research practice, to ensure that ¢ndings
are reproducible and not spurious.
MATERIALANDMETHODS
Study subjects
Asthmatic patients aged15 years or older whowerewill-
ing to give written informed consent were considered
for entry into the run-in period. Patients were required
to have received inhaled corticosteroids (400^1000mg/
dayof inhaledbeclomethasone dipropionate, budesonide
or £unisolide or 200^500mg/day of inhaled FP) for at
least 4 weeks before the study. Patients were also re-
quired to have a documented history of reversible air-
ways obstruction and a 15% increase from baseline in
forced expiratory volume in1second (FEV1) following in-
halation of up to 800mg of salbutamol. Patients who had
changed their regular asthma medication, had a respira-
tory tract infection or required hospitalisation for an
acute exacerbation of asthma in 4 weeks before entry
were excluded. Patients were also excluded if they had
taken oral, depot or parenteral corticosteroids in the
preceding 4 weeks or onX2 occasions in the preceding
12weeks.Patientswith a smokinghistorygreater than10
pack years were also excluded, as were pregnant or lac-
tating women, or those likely to become pregnant dur-
ing the study. Patients were required to be able to
understand and complete a daily record card (DRC) and
measure their peak expiratory £ow (PEF) using a mini-
Wright peak £owmeter.
At the end of the run-in period, patients were re-
quired to meet all of the following additional criteria to
demonstrate that they were symptomatic and their
asthma uncontrolled:
K Ameanmorning PEF recordedon theDRCduring the
last 7 consecutive days of 450% and o85% of thevalue measured in the clinic following the
administration of salbutamol 400mg.
K A cumulative symptom score (day and night) of X8
during the last 7 consecutive days of the run-in, and
symptoms on at least 4 of the last 7 days of the run-in.
Patients with an FEV1 ofr50% of the predicted nor-
mal value were excluded to avoid selection of patients
that were too severe and at risk of early withdrawal for
safety reasons.
Study design
This was a multinational, multicentre, randomised, dou-
ble-blind, double-dummy, parallel-group study carried
out in114 centres in19 countries.The study was approved
by the appropriate regulatory authority and local ethics
committee for each centre and was conducted in accor-
dancewith the Declaration of Helsinki. A 4-week run-in
period was followed by 12 weeks’ treatment and a 2-
week follow-up. Patients discontinued all existing corti-
costeroids, long-acting beta-agonists, leukotriene an-
tagonists and inhaled short-acting beta-agonists on
entry into the 4-week run-in period and were initiated
on FP100mg twice daily via a DiskusTM inhaler (DiskusTM
is a trademark of the GlaxoSmithKline group of compa-
nies).
At the end of the run-in, eligible patients were rando-
mised using patient allocation for clinical trials (PACT)
software to receive either FP100mg twice daily via aDis-
kusTM inhaler and oral montelukast 10mg once daily or
salmeterol/FP combination (SFC)(50/100mg strength)
twice daily via a DiskusTM inhaler plus matching oral pla-
cebo once daily.The FP and SFC DiskusTM inhalers were
identical in shape and colour to ensure blinding of the
study. During the study, short-acting bronchodilators
were replaced by salbutamol for rescue relief as re-
quired.Other regular existing asthma medication could
be continued throughout the study provided the dose
remained constant.The use of oral, parenteral or depot
corticosteroidswas not allowedduring the study, except
where documented for the treatment of exacerbations.
Assessments
At the screening visit, DRCs were issued to each patient
to record the following information: the highest of three
morning and the highest of three evening PEF readings,
the number of times salbutamol was administered for
symptomatic relief, daytime symptom score on a 6-point
scale (0 = no symptoms; 5 = symptoms so severe that
the patient is unable toworkor performnormal daily ac-
tivities), night-time symptom score on a 5-point scale (0
= no symptoms; 4= symptoms so severe that thepatient
is unable to sleep) and changes in asthma medication.
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of treatment. Lung function (FEV1) was measured at all
clinic visits. The incidence and severity of exacerbations
of asthma were recorded. Exacerbations were classi¢ed
as mild (a deterioration in asthma requiring a clinically
relevant increase in salbutamol use de¢ned asmore than
three additional inhalations per 24-h periodwith respect
to baseline for42 consecutive days), moderate (requir-
ing oral corticosteroids and/or antibiotics) or severe (re-
quiring a hospitalisation).
Patient assessment of satisfactionwith treatmentwas
recorded at the end of the run-in and the end of the
treatment period on a 5-point scale ranging from very
satis¢ed to very dissatis¢ed. Physician assessment of the
e¡ectiveness of study treatment was recorded at the
end of the treatment period on a 5-point scale ranging
from very e¡ective to very ine¡ective.Compliance with
the study treatmentwas assessedbyrecording the num-
ber of doses remaining in the DiskusTM inhaler and by
counting the number of tablets returned to the clinic by
the patient.
The safety and tolerability of the study treatments
wasmonitoredbyrecording adverse events at each clinic
visit and by monitoring the number of patient withdra-
wals. The patient’s oropharynx was examined at each
clinic visit during the treatment period and swabs taken
if candidiasis was suspected.
Statistical analysis
Theprimarye⁄cacy variablewas themeanmorning PEF
recorded on the DRC.The population used for analysis
was de¢ned as all randomised patients with at least 1
dayrecordedon theDRC, but excluding thosewhowere
incorrectly randomised because they failed major inclu-
sion criteria (thereduced ITT population).The twomajor
criteria for exclusion were that patients did not demon-
strate the requiredpeak £owreversibilityor had too few
symptoms during the run-in. Safety was assessed in the
safety population, de¢ned as all randomised patients
who took studymedication. Assuming a standard devia-
tion of PEF values of 50 l/min in the population studied
and the requirement for 90% power, it was calculated
that 470 evaluable patients would be required to detect
a di¡erence between treatments of15 l/min at the 5% le-
vel of signi¢cance. PEF measurements were analysed
usingrepeatedmeasuresmixedmodel ANOVA.PEFdata
throughout the study were aggregated for each patient
into six 14-day periods; those periods with less than 8
valid scoring days were considered missing in the ana-
lyses. For symptom score and salbutamol use, daily
symptom-free andrescue-free scoreswereused. In all ef-
¢cacy analyses, the average value over the run-in period
was used as a baseline covariate. Other covariates in-
cluded 14-day period (a within-subjects factor with sixlevels), treatment, gender, age, height and country (be-
tween subjects). In the PEF analyses, the country e¡ect
(with 19 levels) was considered random, whereas in the
symptom-free and rescue-free analyses it was consid-
ered ¢xed. The between-period correlation (for re-
peated PEF data) and the day-to-day correlation (for
repeated symptom-free and rescue-free data) were as-
sumed to have a ¢rst order autoregressive structure.
Clinic FEV1was also analysed by mixed model ANOVA,
with the baselinemeasurement as covariate.
Symptom score and salbutamol use (rescue medica-
tion) were analysed using generalised linear modelling
after dichotomisation of the daily scores as symptom-
free (y/n) andrescue-free (y/n), respectively.Thebinomial
distributionwith logit link and the generalised estimating
equation method (17) for repeated data were used.The
logit link implies that the e¡ect of treatment on the
probabilities of having a symptom-free or rescue-free
day is expressedbymeans of an oddsratio of SFCrelative
to FP plusmontelukast.
Comparison between treatment groups of the num-
ber of patients who withdrew or had exacerbations of
asthma was done using a chi-square test. The time to
¢rst exacerbationwas analysedusing Kaplan^Meier sur-
vival analysis with the log rank test. For the assessment
of patient and physician satisfaction with treatment,
comparisons were based on the response obtained at
the end of treatment using theWilcoxon rank sum test.
All the above non-parametric tests were performed
strati¢ed by (and hence adjusted for) country.
RESULTS
Patient characteristics
A total of 1168 patients were enrolled into the study, of
whom 806 were randomised to study medication. One
patient did not receive studymedication, so 805 patients
were included in the safety population (used for the ad-
verse event tables). Three hundred and sixty two pa-
tients were withdrawn from the study before
randomisation, mainly because of failing the criteria for
entry into the treatment period. During the statistical
analysis, a further 81 patients were excluded due to not
meeting the pre-randomisation eligibility criteria to ar-
rive at the reduced ITT population of 725 patients (356
in the SFC and 369 in the FPplusmontelukastgroup).The
demographic and baseline clinical characteristics of each
treatment group are outlined in Table 1. The treatment
groupswerewellmatched for sex, age and lung function.
The compliance with study medication was high in
both groups; 96% of patients in both treatment groups
returned the correct number of doses in the DiskusTM
inhaler and 97% in both groups returned the right
number of tablets according to the protocol require-
ments.
TABLE 1. Patientcharacteristics (reduced intent-to-treat population)
SFC FP plusmontelukast
Patients, n: 356 369
Sex, n (%)
Male 164 (46%) 165 (45%)
Female 192 (54%) 204 (55%)
Mean age, years (range) 43 (15^75) 43 (14^79)
Current smoker (%) 6.2% 6.2%
Ex-smoker (%) 20.8% 24.4%
Meannumberof pack years (range) 5 (0^10) 5(0^10)
Mean % predicted FEV1 (SD): 75.8% (15.3%) 74.3% (16.1%)
Reversibility, % change frombaseline (SD) 27.4% (13.5%) 27.0% (12.6%)
FEV1 = forced expiratory volumein1second;FP = £uticasonepropionate; SD = standarddeviation;SFC = salmeterol/£utica-
sone propionate.
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FIG. 1. Mean morning peak expiratory £ow (PEF) at baseline and during 12 weeks’ treatment with either salmeterol/£uticasone
propionatecombination (SFC; 50/100 mg twicedaily) or £uticasonepropionate (FP) 100 mgtwicedailyplusoralmontelukast10mgonce
daily.Error bars show standard errorof themean.
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PEF
Mean baselinemorning PEF was similar in the two treat-
ment groups: 371and 367 l/min for the SFC group and FP
plusmontelukast group, respectively.Meanmorning PEF
increased frombaseline in both treatment groups during
the studyperiod (Fig.1).The adjustedmean increase from
baseline in the SFC groupwas 36 l/min over the12-week
period and19 l/min in the FP plusmontelukast group.The
di¡erence was 17 l/min (95% CI 12^22 l/min; Po0.05)
which did not signi¢cantly change over the 2-weekly in-
tervals throughout the treatment period (P=0.39; Fig.1;
Table 2). In both treatment groups, the improvement in
mean morning PEF from baseline was evident 1 week
after starting treatment (Fig. 2). The onset of improve-
mentwas, however, signi¢cantly faster in the SFC group
with a signi¢cant di¡erence already recorded 24h after
starting treatment (mean treatment di¡erence 16.9 l/min; 95% CI1.9^32 l/min; P=0.03).The results for the pri-
mary e⁄cacy variable were supported by those for the
secondary e⁄cacy variables.The increase from baseline
in evening PEF over the 12-week treatment period was
signi¢cantly greater in the SFC group, with an adjusted
mean improvement of 29 l/min compared with 14 l/min
in the FP plusmontelukastgroup (Table 2).The di¡erence
was 15 l/min (95% CI 11^20 l/min; Po0.05). There was
some evidence that this di¡erence increased in time from
12 l/min in the ¢rst two-weekly interval to18 l/min in the
sixth two-weekly interval.
Clinic FEV1
In both treatment groups, there was an improvement in
FEV1 from baseline during the study period. At baseline,
the mean FEV1 value in the SFC group was 2.47 l, which
increased to 2.73 l at the end of 12 weeks (Table 2).This
was signi¢cantly greater (Po0.05) than the FEV1increase
TABLE 2. E⁄cacy variables atbaseline andduring treatmentinpatientswhoreceivedsalmeterol/£uticasonepropionate com-
bination (SFC; 50/100mg) twice daily or £uticasone propionate (FP) 100mg twice daily plus montelukast10mg once daily for12
weeks. analysis of reduced intent-to-treat population
Variable SFC FP plusmontelukast Oddsratio P value
Baseline Weeks1^12 Baseline Weeks1^12
Meanmorning PEF (l/min) (SEM) 370.875.1 407.77 2.2 367.374.9 388.27 2.1 F 0.0001
Mean evening PEF (l/min) (SEM) 385.775.3 416.572.2 380.374.9 395.572.1 F 0.0001
Clinic FEV1 (L) (SEM) 2.4770.04 2.737 0.03 2.4170.04 2.587 0.03 F 0.0001
Median % symptom-free days 7.1 50.0 7.0 38.5 1.32 0.017
Median % symptom-free nights 32.1 78.6 30.3 71.4 1.28 0.033
Median % rescue-free days 23.5 71.4 20.7 66.7 1.29 0.03
Median % rescue-free nights 53.6 92.9 56.7 85.7 1.15 0.26
P-values arebasedonmixedmodel analysis of variance orgeneralisedlinearmodel. SEM = standard errorofthemean;FEV1 =
forced expiratory volume in1second,PEF= peakexpiratory £ow.
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FIG. 2. Meanmorning peakexpiratory £ow (PEF) at baseline
and during the ¢rst 7 days of treatment with either salmeterol/
£uticasone propionate combination (SFC; 50/100 mg twice daily)
or £uticasone propionate (FP) 100 mg twice daily plus oral mon-
telukast10mg once daily.Error bars show standard error of the
mean.
0 4 8 12 1-12
2.3
2.4
2.5
2.6
2.7
2.8
SFC
FP + montelukast
M
ea
n 
FE
V
1 
(L
)
Treatment week
P<0.05
FIG. 3. Forced expiratory volume in 1s (FEV1; adjusted mean
values 7 standard error of the mean) at baseline and during 12
weeks’ treatment with either salmeterol/£uticasone propionate
combination (SFC; 50/100 mg twice daily) or £uticasone propio-
nate (FP) 100 mg twicedailyplusoralmontelukast10mgoncedaily.
238 RESPIRATORYMEDICINEin the FP plus montelukast group, which rose to 2.58 l
from a baseline of 2.41l (mean treatment di¡erence 0.11l;
95% CI 0.06^0.16 l;Po0.05) (Fig. 3).
Symptom-free days and nights
The percentage of symptom-free days and nights
improved from baseline in both treatment groups
(Table 2).Thepatients in the SFC groupwere signi¢cantly
more likely to have a symptom-free day during the study
period (odds ratio 1.32; 95% CI 1.05^1.65; Po0.05). The
results for symptom-free nights were very similar; the
chances of a symptom-free night were signi¢cantly high-
er in the SFC group than in the FP plus montelukastgroup for weeks 1^12 (odds ratio 1.28; 95% CI 1.02^1.61;
Po0.05).
Rescuemedication use
The number of rescue-free days and nights, i.e. those
days andnightswhen salbutamolwas notused, increased
from baseline in both groups during the 12-week
treatmentperiod (Table 2).Thepatients in the SFCgroup
were signi¢cantly more likely to have a rescue-free day
during the study period (odds ratio 1.29; 95% CI 1.02^
1.63; P=0.03). The chances of a rescue-free night were
also numerically higher in the SFC group than in the FP
plus montelukast group for weeks 1^12, but this did not
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FIG. 4. Number of patients in each study arm who remained
free of an asthma exacerbation over the 12 weeks of the study,
plotted as a percentage of the number who started study treat-
ment (Kaplan^Meier analysis).Patients received either salmeter-
ol/£uticasonepropionate combination (50/100 mg twice daily) or
£uticasonepropionate (FP) 100 mg twice dailyplus oralmontelu-
kast10mgonce daily.
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P=0.26).
Exacerbations ofasthma
The number of patients who had at least one asthma ex-
acerbation (any severity) was signi¢cantly lower in the
SFC group (34; 9.6%) than in the FP plus montelukast
group (54; 14.6%; Po0.05). The percentage of patients
whohad at leastone asthma exacerbation of eithermod-
erate or severe intensity was 4.8% in the SFC group and
8.4% in the FP plusmontelukast group; this di¡erence did
notreach statistical signi¢cance (P=0.07).The time to the
¢rst exacerbation was signi¢cantly longer in the SFC
group than in the FP plus montelukast group (Po0.05)
(Fig. 4).
Patient/physician satisfaction with treatment
The percentage of patients at the end of the treatment
period who were either very satis¢ed or satis¢ed with
the treatment they had received was signi¢cantly higher
in the SFC group (92.9%) than in the FP plusmontelukast
group (83.5%;Po0.05).Thepercentage of physicianswho
assessed the treatment as very e¡ective or e¡ectivewas
also signi¢cantly higher in the SFC group (79.6%) than in
the FP plusmontelukast group (72.6%; Po0.05).
Safety
Adverse events
The overall incidence of adverse events in the safety po-
pulation was similar in the SFC group (44%) and the FP
plusmontelukastgroup (42%).Respiratory systemevents
predominatedduring treatment, with themost frequent
event in both groups being an exacerbation of asthma
(Table 3). Oropharyngeal candidiasis occurred in three
patients in the SFC group and one in the FP plusmonte-
lukast group.TABLE 3. Adverse events reportedbymore than ¢ve patients
Exacerbation of asthma
Commoncold
Upper respiratory tract infection
Headache
Sore throat
In£uenza
Bronchitis
FP = £uticasone propionate; SFC = salmeterol/£uticasone proEleven serious adverse events (SAEs) were reported
(four in the SFC group and seven in the FP plusmontelu-
kast group) of which none were drug-related.The most
common SAE was hospitalisation due to an asthma ex-
acerbation; this occurred in one patient in the SFCgroup
and two in the FP plus montelukast group. Signi¢cantly
fewer patients withdrew from the SFC group during
the treatmentperiod (19; 5%) than from the FPplusmon-
telukast group (37; 10%) (Po0.05). The main reason for
these withdrawals was an adverse event (32 out of 56
withdrawals; 57%).
DISCUSSION
The results of this study showed that SFC (salmeterol
50mg/FP 100mg) administered twice daily for 12 weeks
was more e¡ective than FP100mg twice daily plus mon-
telukast 10mg once daily for the treatment of sympto-
matic patients with moderate to severe asthma; SFCin the safetypopulation
Numberof events (%)
SFC FP plusmontelukast
(n=404) (n=401)
39 (10%) 50 (12%)
30 (7%) 31 (8%)
15 (4%) 9 (2%)
12 (3%) 18 (4%)
10 (2%) 3 (o1%)
9 (2%) 10 (2%)
4 (o1%) 10 (2%)
pionate.
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symptom control and reduced the frequency and time-
to-¢rst exacerbation. These results, obtained from a
multicountry patient population, reproduce those of an
earlier study performed in a U.S. population (16).
This study was designed to assess the bene¢ts of add-
ing either salmeterol or montelukast to patients already
taking inhaled corticosteroids.Criteria for inclusion into
the study ensured that patients were asthmatic (as de-
monstrated by their reversibility), symptomatic and re-
quired step-up therapy. The requirement for the
subjects to be reversible to salbutamol may have poten-
tially favoured the SFC group over the FP plus montelu-
kast group. However, reversibility to short-acting
bronchodilators is central in the correct diagnosis of
asthma andhasbeenused as a patient selection criterion
in other large studies investigating the clinical bene¢t of
adding montelukast to inhaled corticosteroid therapy
(15,18). The study duration of 12 weeks was chosen as it
has previously been shown to be su⁄cient to demon-
strate the maximal e¡ect of both salmeterol (7,8) and
montelukast (15).
In the current study, the di¡erence inmorning PEF be-
tween the groups of 17 l/min was close to the value per-
ceived by patients to be of a clinical bene¢t (19). In
addition, the improvement in the other endpoints
achieved in the SFC groupwas accompaniedby fewerpa-
tient withdrawals and a smaller number of asthma ex-
acerbations. The percentage of patients with at least
one exacerbation was signi¢cantly lower in the SFC
group, as was the time to ¢rst exacerbation. Reduction
in the frequency of asthma exacerbations is important in
decreasing morbidity and mortality in asthma patients,
improving their quality of life and reducing the costs as-
sociatedwith the disease.
As with all controlled clinical trials, questions remain
around thegeneralisabilityof these ¢ndings to daily prac-
tice. Patients in the current trial were selected before
entering the study and had very high levels of compli-
ance. Studies that addressed this issue using retrospec-
tive data from clinical practice found that in a real-world
setting the combination of salmeterol and FP or the
combination of salmeterol and inhaled corticosteroids
provides superior clinical bene¢t compared to inhaled
corticosteroids plus leukotriene modi¢ers.This was de-
monstrated by less visits to the emergency department
and hospital, and less use of rescue medication by pa-
tients on the combination of salmeterol and FP or other
inhaled corticosteroids (20,21).
In the current study, the di¡ering e⁄cacy cannot be
attributed to the di¡erences in compliance in the taking
of study treatment. As mentioned before and as ex-
pected in the study setting, compliancewith studymed-
ication was high in both treatment groups. In both
groups, the need for an additional inhaler for rescue use
remains, meaning that outside the clinical trial setting indaily practice in the montelukast group, treatment with
three separate drugs is required. The use of multiple
routes and daily administrations of treatment has been
shown to contribute to poor compliance (22).
At the end of the study, patient satisfactionwith treat-
ment was high.The number of patients whowere either
very satis¢ed or satis¢edwith the studymedicationwas
signi¢cantly higher in the SFC group. Similar ¢ndings
have been reported in a recently published study (23). In
the current study, this result is notable since the study
medication was administered double-dummy, i.e. both
groups used two inhalations and one tablet per day, yet
patients and investigators recorded a preference for
SFC.
In summary, in patients symptomatic on a low dose of
inhaled corticosteroids, both treatmentswere e¡ective,
although the improvement seen with SFC was consis-
tently better, irrespective of study endpoint measured.
Both treatments were equally well tolerated.These re-
sults strengthen the ¢ndings of previously reported stu-
dieswithbothmontelukast and za¢rlukast (15,24,25) and
con¢rm that the combination of salmeterol and FP is the
preferred option for patients uncontrolled on a lowdose
of inhaled corticosteroids.
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